恩華藥業(002262.SZ):化學藥品鹽酸咪達唑侖口服溶液獲批上市
格隆匯4月18日丨恩華藥業(002262.SZ)公佈,公司於近日獲得國家藥品監督管理局核准簽發的化學藥品鹽酸咪達唑侖口服溶液的《藥品註冊證書》。
鹽酸咪達唑侖口服溶液用於兒童診斷或治療性操作前以及操作過程中的鎮靜/抗焦慮/遺忘;也可用於兒童術前鎮靜/抗焦慮/遺忘。
此次獲得鹽酸咪達唑侖口服溶液的《藥品註冊證書》,豐富了公司在麻醉領域的產品管線,有利於提升公司的市場競爭力,其上市銷售將對公司今後業績的提升產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.